Prucalopride for gastrointestinal motility disorders a review of clinical effectiveness
In 2012, the Canadian Drug Expert Committee (CDEC) recommended prucalopride not be listed for the treatment of chronic constipation, citing unclear clinical effectiveness in the population of interest (patients who had previously failed laxative therapy). This Rapid Response report aims to review th...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
December 6, 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | In 2012, the Canadian Drug Expert Committee (CDEC) recommended prucalopride not be listed for the treatment of chronic constipation, citing unclear clinical effectiveness in the population of interest (patients who had previously failed laxative therapy). This Rapid Response report aims to review the clinical effectiveness of prucalopride for chronic constipation, ileus, refractory gastroparesis, and intestinal pseudo-obstruction compared to other medications and placebo |
|---|---|
| Physical Description: | 1 PDF file (21 pages) illustration |